Purdue Pharma LP pleaded guilty to criminal charges over the handling of the company’s addictive prescription painkiller OxyContin, capping a deal with federal prosecutors to resolve an investigation into the drugmaker’s role in the U.S. opioid crisis.

Pfizer Inc. applied to U.S. health regulators for emergency use authorization (EUA) of the company’s Covid-19 vaccine, the first such application in a major step toward providing protection against the new coronavirus.

Johnson & Johnson was ordered by a New York state judge to pay $120 million in damages to a Brooklyn woman and her husband, after she blamed her cancer on asbestos exposure from using the company’s baby powder.

Final results from Pfizer Inc.’s Covid-19 vaccine trial showed the company’s shot had a 95% success rate and two months of safety data, paving the way for the drugmaker to apply for an emergency U.S. authorization within days.

Warren Buffett, one of America’s best-known investors, is backing multiple pharmaceutical companies developing therapies aimed at curbing the ongoing global Covid-19 pandemic.

Johnson & Johnson secured more than $1 billion in additional funding for the company’s Covid-19 vaccine research through an expansion of J&J’s partnership with the Biomedical Advanced Research and Development Authority (BARDA), a division of the U.S. Department of Health and Human Services.

Johnson & Johnson launched a new late-stage trial in Britain to test a two-dose regimen of the company’s experimental Covid-19 vaccine among thousands of volunteers, as the U.S. drugmaker’s clinical studies expand by geography and type.

Johnson & Johnson and the U.S. Department of Health and Human Services expanded an agreement to support the next phase of Covid-19 vaccine candidate research and development, the company said.

A combination of Canadian drug developer Medicago’s experimental Covid-19 vaccine and a booster from Britain’s GlaxoSmithKline will enter a large study with more than 30,000 volunteers in 2020.

Shortages of flu shots this year are not related to drugmakers ramping up production of potential Covid-19 vaccines, the head of vaccines at GlaxoSmithKline (GSK) said.